SNUS Sonus Pharmaceuticals (MM)

Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) today announced that it will release second quarter financial results on Friday, August 3, and hold its quarterly conference call at 8:30 A.M. PT/11:30 A.M. ET. The second quarter conference call will be broadcast live and can be accessed on the Sonus web site at www.sonuspharma.com/events.html. The call will be archived at the same link. A telephone replay of the call will be available from August 3, 10:30 A.M. PT/1:30 P.M. ET, for one week at 800-405-2236 or 303-590-3000 for international calls; Conference ID: 11094009. About Sonus Pharmaceuticals Located near Seattle, Sonus Pharmaceuticals, Inc. is focused on the development of cancer drugs that are designed to provide better efficacy, safety, tolerability, and ease of use. The Company�s lead product candidate, TOCOSOL� Paclitaxel, is currently in a Phase 3 pivotal trial for the potential treatment of metastatic breast cancer. Adjudicated data from the Phase 3 trial are expected to be available by the end of the third quarter of 2007. TOCOSOL Paclitaxel is an injectable, ready-to-use formulation of paclitaxel that may reduce treatment-limiting side effects and improve anti-tumor activity. In addition to the continuing development of TOCOSOL Paclitaxel, Sonus moved its second product candidate, TOCOSOL Camptothecin, into a Phase 1 clinical trial in September 2006. For additional information on the Company, including past news releases, please visit www.sonuspharma.com. Taxol� is a registered trademark of Bristol-Myers Squibb Company.